Alvimopan
From Wikipedia, the free encyclopedia
|
Alvimopan
|
|
| Systematic (IUPAC) name | |
| 2-([(2S)-2-([(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl) -3-phenylpropanoyl]amino)acetic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C25H32N2O4 |
| Mol. mass | 424.53 g/mol |
| SMILES | & |
| Synonyms | Alvimopan, Entereg |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Alvimopan (Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood-brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawals.[1][2] The Food and Drug Administration reviewed the safety and efficacy data for alvimopan and approved its use in May 2008.[3]
[edit] References
- ^ Neary P, Delaney P (2005). "Alvimopan". Expert Opin Investig Drugs 14 (4): 479–88. doi:. PMID 15882122.
- ^ Schmidt WK (2001). "Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist". Am J Surg 182 (5A Supp): 27S–38S. doi:. PMID 11755894.
- ^ FDA press release - FDA Approves Entereg to Help Restore Bowel Function Following Surgery

